Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX43 in advanced gynecologic malignancies
CTR20244830Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in Cervical Cancer (CC), ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), gynecological cancer, sponsored by HyBioPharma. Started Feb 2025; status: active.
02
Drugs
HLX43
03
Conditions
Cervical Cancer (CC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)gynecological cancer
Beyond the preview
Go deeper on CTR20244830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244830.